EN DE
Watch Cybin Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Cybin Inc. (HELP) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Cybin Inc. stock C$8.49, price C$10.89, that is 22.0% below the price, quality 30 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CA · ISIN CA4234921076

CI Cybin Inc. logo Thin data Nov 17, 2026

Cybin Inc.

HELP · NEO

Expensive (fair value 22% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Fair value C$8.49 · Overvalued 
Quality 30/100 
Negative free cash flow 
Trails peers (2/6) 
Narrow moat 9/100
Thin data 
Estimate
Watch Cybin Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

C$133.00 C$5.49 Fair Value C$8.49 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

60‑month range C$5.49 – C$133.00 · fair‑value band C$6.37 – C$10.61 · the C$10.89 price screens above the C$8.49 fair value. As of Nov 17, 2026.

Follow Cybin in your weekly email

Every Wednesday you see whether Cybin is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions.

Show moreShow less

It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders.

The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds.

It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.

Stock analysis

Cybin Inc. (HELP) currently trades at C$10.89, while our estimate is C$8.49, 22% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: C$6.37 (bear) to C$10.61 (bull), the price of C$10.89 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Cybin Inc. reported revenue of $0 in FY2026 versus $0 in FY2022. Reported net income was −$148M in FY2026.

Key figures

Market cap C$796M (≈ $556M) Small · EPS (TTM) C$−5.91 · Return on equity −86.9% · Return on assets (EBIT) −62.0% (5-year average) · Free cash flow −$135M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 45% below its 52-week high and 99% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −22%, HELP screens richer than that median.

Fair Value

Bear C$6.37 Fair Value C$8.49 Bull C$10.61
Price C$10.89 · Downside -22.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 30/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 25
Are margins and returns getting better?
Cashflow 27
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 45
How calm the share price moves, does not count
Price momentum 69
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 53
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

HELP screens overvalued: fair value 22% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Cybin Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 2/4 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside −22.0% · Above median
Profitability
Return on assets −58.9% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.40× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)4 · sector 1
FUTURE (revenue growth)0 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs HELP
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs HELP
Samsung Biologics Co 207940 1,414,000 KRW 1,552,100 KRW +10% vs HELP
argenx SE ARGX $950.95 $908.40 −4% vs HELP
CSL Limited CSL A$199.55 A$186.49 −7% vs HELP
Moderna, Inc MRNA $215.27 $135.64 −37% vs HELP
BeOne Medicines AG 6160 HK$247.40 HK$152.92 −38% vs HELP
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs HELP
Celltrion, Inc 068270 213,000 KRW 74,945 KRW −65% vs HELP
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs HELP

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cybin Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Cybin Inc. Fair Value". https://www.fairvalue-calculator.com/stock/HELP

Frequently asked questions

Is Cybin Inc. (HELP) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is C$8.49 versus a price of C$10.89, about 22% lower (overvalued).
What is the fair value of HELP?
Our estimate for Cybin Inc. is C$8.49 (as of Nov 17, 2026), built from audited fundamentals. The current price: C$10.89.
What is the quality score of HELP?
Cybin Inc. has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cybin Inc. (HELP)?
Our calculated price target is the estimate of C$8.49 (as of Nov 17, 2026). Cautious scenario C$6.37, optimistic scenario C$10.61. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Cybin Inc. stock forecast for 2026?
Our estimate puts fair value at C$8.49, about 22% lower versus a price of C$10.89 (overvalued). Cautious scenario C$6.37, optimistic scenario C$10.61. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Cybin Inc. (HELP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cybin Inc. it is C$8.49 per share (as of Nov 17, 2026), against a price of C$10.89.
Is Cybin Inc. stock overvalued or undervalued in 2026?
As of Nov 17, 2026, HELP trades above its calculated fair value: price C$10.89, fair value C$8.49, a gap of about −22% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HELP?
No. The price is what the market pays today (C$10.89); the fair value is what the company's own numbers justify (C$8.49). For Cybin Inc. the two are C$2.40 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cybin Inc. worth?
The market values Cybin Inc. at about C$796M (market capitalisation, as of Nov 17, 2026). Per share that is C$10.89; our models calculate a fair value of C$8.49 per share.
What do the bullish and bearish scenarios say about HELP?
Our models span a range for Cybin Inc.: cautious scenario C$6.37, base C$8.49, optimistic C$10.61 per share (as of Nov 17, 2026, price C$10.89). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Cybin Inc. (HELP)?
Balance-sheet figures for Cybin Inc. (as of Nov 17, 2026): return on equity −86.9%. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is HELP from its 52-week high?
Cybin Inc. trades at C$10.89, about 45% below its 52-week high of C$19.71 and 99% above the low of C$5.49 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of C$8.49 is for.
Which stocks are comparable to Cybin Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cybin Inc. stock attractive at the current price?
The data as of Nov 17, 2026: price C$10.89, calculated fair value C$8.49 (−22%), Quality Score 30/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Cybin Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cybin Inc. (HELP)?
The closing price on Nov 16, 2026 was C$10.89. Our estimate is C$8.49, about 22% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cybin Inc. right now?
The price sits above even our optimistic bull case (C$10.61). The favourable scenario is already priced in. Weak quality (30/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Cybin Inc.

How large is the market capitalisation of Cybin Inc. (HELP)?
The market capitalisation of Cybin Inc. is C$796M (≈ $556M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Cybin Inc. (HELP)?
Earnings per share at Cybin Inc. are C$−5.91. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Cybin Inc. (HELP)?
The return on equity (ROE) of Cybin Inc. is −86.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cybin Inc. (HELP)?
On an EBIT basis the return on assets of Cybin Inc. is −62.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Cybin Inc. (HELP) generate?
The free cash flow of Cybin Inc. is −$135M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Cybin Inc. in the live analysis

One click puts Cybin Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.